49Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
South Africa
Neuroscience Intelligence
South Africa neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #41 of 50 · Data maturity A · Research score 28.9 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
5Recruiting trials
22Publications
29Institutions
Executive interpretation
South Africa ranks #41 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Pfizer50 recruiting
Merck Sharp & Dohme LLC42 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
Novo Nordisk A/S41 recruiting
Sumitomo Pharma America, Inc.30 recruiting
Bayer22 recruiting
Forest Laboratories20 recruiting
AbbVie20 recruiting
Bial - Portela C S.A.10 recruiting
Astellas Pharma Europe B.V.10 recruiting
Disease activity
Parkinsons7trials
Alzheimers5trials
Depression5trials
Pain Neuropathy4trials
Autism4trials
Stroke3trials
Epilepsy2trials
Schizophrenia2trials
Bipolar Disorder2trials
Multiple Sclerosis1trials
Research institutions
University of JohannesburgOpenAlexlinked institution
University of the Western CapeOpenAlexlinked institution
Stellenbosch UniversityOpenAlexlinked institution
University of South AfricaOpenAlexlinked institution
Nelson Mandela UniversityOpenAlexlinked institution
University of Cape TownOpenAlexlinked institution
Durban University of TechnologyOpenAlexlinked institution
University of PretoriaOpenAlexlinked institution
Johannesburg HospitalOpenAlexlinked institution
Department of HealthOpenAlexlinked institution
Clinical evidence trail
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT05567796A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightACTIVE_NOT_RECRUITING
NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaRECRUITING
NCT05196035A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT05540522A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or OlderCOMPLETED
NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)COMPLETED
NCT05064059A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)COMPLETED
NCT04955626To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.COMPLETED
NCT04777409A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)COMPLETED
NCT04533529A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With SeltorexantCOMPLETED
Research evidence trail
PUBMEDSuicidal thoughts and behaviours in Cape Town: A cross-sectional study of prevalence and social, contextual, and clinical correlates.2026-12-01
PUBMEDFive-year outcomes in a randomised controlled trial of prolonged exposure therapy and supportive counselling for post-traumatic stress disorder in adolescents: a task-shifted intervention.2026-12-01
PUBMEDSystematic Review and Meta-analysis of Prevalence of Mental Disorders and Suicidality Among Children and Adolescents Living with HIV in South Africa.2026-10-07
PUBMEDSexual orientation and clinical outcome trajectories over 24 months of treatment in first-episode schizophrenia.2026-10-01
PUBMEDPsychiatric Comorbidities in 7-12 Year Old Children Diagnosed With ADHD in South Africa: A Record Review.2026-10-01
PUBMEDExamining the structure of post-traumatic stress symptoms in South Africa: A latent class approach.2026-09-15
PUBMEDDigital health technologies for supporting home-based rehabilitation and management of children with cerebral palsy: a scoping review.2026-08-19
PUBMEDExploring occupational therapists' perceptions of the use of functional electrical stimulation in adult stroke rehabilitation.2026-06-09
PUBMEDSelf-perceived fatigue in relation to activity and participation in adolescents and adults with cerebral palsy living in urban South Africa.2026-05-01
PUBMEDUsability, adherence and efficacy of coach-augmented dHealth cognitive behavioural therapy for insomnia in South African sexual assault survivors: a pilot study.2026-01-01
OPENALEXConsensus statement on concussion in sport: the 6th International Conference on Concussion in Sport–Amsterdam, October 20222023-06-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.